Multimodal Analysis of Anticancer Drug Testing In Tumor-Specific 3D Cell Culture Models

May 12, 2021
Julia Kirshner, Ph.D. Founder & CEO, zPREDICTA, Inc.

The high rates of clinical failure of new anticancer drugs highlight that the standard approaches to evaluate drug efficacy do not faithfully reproduce human biology, and thus, do not accurately represent the disease processes or response to treatment. In this webinar we will discuss how tumor-specific 3D culture models can be used to improve the accuracy of drug testing. We will also highlight the advantages of using multimodal readout to evaluate multiple parameters associated with cellular response to anticancer drugs.

Joint webinar with LabCorp Drug Development

Tumor Specific 3D Cell Culture Models for Accurate Testing of Anticancer Agents

April 21, 2021
Julia Kirshner, Ph.D. Founder & CEO, zPREDICTA, Inc.
Sumitra Urs, Ph.D., Scientist, Scientific Development, Covance

In this webinar we will discuss the advantages of a 3D culture approach over the traditional methods, with particular emphasis on the importance of tumor microenvironment and tissue-relevant extracellular matrix (ECM) in obtaining accurate drug response data. We will highlight the unique advantages zPREDICTA’s tumor-specific 3D culture platform where both cellular and extracellular components of tumor microenvironment are reconstructed in vitro. Clinical study data demonstrate high correlation between drug efficacy measured in our platform and clinical response. The ability of zPREDICTA’s platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Expert Insight: Automating tumor-specific 3D cultures for anti-cancer drug screening

March 24, 2020
Julia Kirshner, Ph.D.
Founder & CEO, zPREDICTA, Inc.

In this webinar we will discuss how 3D cell culture overcomes the limitations of traditional 2D culture when it comes to predicting the therapeutic potential of pharmaceutical compounds in development. We will describe how our Reconstructed Lung 3D culture platform (r-Lung) has successfully been adopted for testing of anti-cancer agents in high-throughput screening (HTS) format using the Tecan Freedom EVO® liquid handler and Tecan D300e Digital Dispenser, and how the platform provides a physiologically-relevant, automated 3D HTS system that can be incorporated throughout the drug development workflow for reliable identification of anti-cancer agents.

3D Cell Culture Technologies In Drug Development

January 31, 2019
Julia Kirshner, Ph.D.
Founder & CEO, zPREDICTA, Inc.

In this webinar we discuss zPREDICTA’s 3D disease models and their use in drug development emphasizing the capacity of our patient-derived platform to mimic the native architecture of human tissues in an organ- and disease-specific manner and its high correlation with clinical response.

Novel 3D Culture Technologies Utilizing Patient-Derived Tissue

July 12, 2016
Julia Kirshner, Ph.D. 
Founder & CEO, zPREDICTA, Inc.

In this webinar we summarize the current state of 3D culture technologies and highlight relevant applications of each platform.

Human cells have been grown in culture since the 1950s. However, conventional cell culture models lack tissue microenvironment, and thus, have limited physiological relevance. Emerging 3D culture systems are starting to incorporate various components of tissue microenvironment to better replicate the biology of human tissues.


Start typing and press Enter to search